AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33849913
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (2,000 IU orally daily for 1 year)
Trial: 35680252
Drug: Cannabis products
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabis products added to a behavioural pain management and prescription opioid taper support programme
Trial: 36395262
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (GP)
Trial: 36252745
Drug: Duloxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine (60 mg daily from the day of surgery to postoperative day 6)
Trial: 32100500
Drug: Wheat-grain moxibustion
RxNorm normalized name: Light wheat grain
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat-grain moxibustion at Yinbai (SP 1), performed once a day with an interval of 1 day between two 3-day treatments.
Trial: 32100500
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of dydrogesterone tablet, 10 mg twice a day.
Trial: 35180298
Drug: Acetaminophen (500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (500mg or 1000mg 6-hourly for 72 hours)
Trial: 35569002
Drug: Oral Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Misoprostol (OM) 50 µg four hourly for 48 hours
Trial: 34052421
Drug: Ultrasonic scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic scaling + oral hygiene instructions
Trial: 34052421
Drug: Ultrasonic scaling/oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic scaling/oral hygiene instructions + aPDT
Trial: 32558469
Drug: Systematic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months.
Trial: 32558469
Drug: Guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided treatment (screening with Xpert MTB/RIF test, urinary lipoarabinomannan test, and chest radiography).
Trial: 32558469
Drug: Systematic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systematic treatment
Trial: 35969436
Drug: Reminder group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reminder group (daily reminders via WeChat)
Trial: 34533505
Drug: Machine Learning
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Machine Learning (ML) algorithm for predicting unplanned subsequent surgery after intramedullary nailing (IMN) for TSFs
Trial: 35945566
Drug: IV alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV alteplase (5mg) followed by continuous IV infusion of m‐proUK (40 mg/h during 60 min)
Trial: 35945566
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care with alteplase (0.9 mg/kg)
Trial: 33805908
Drug: Tetrodotoxin (TTX)
RxNorm normalized name: Tetrodotoxin
DrugBank: Tetrodotoxin (DB05232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrodotoxin (TTX) 30 µg BID
Trial: 35549912
Drug: HIPEC with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC with high-dose mytomicin-C (35 mg/m2)
Trial: 35549912
Drug: Personalized systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized systemic chemotherapy (both arms)
Trial: 36209381
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of triamcinolone acetonide after fractional CO2 laser treatment
Trial: 36209381
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of triamcinolone acetonide after microneedling (MN) treatment
Trial: 34562648
Drug: 5-Aminolaevulinic Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-Aminolaevulinic Acid Photodynamic Therapy (ALA PDT)
Trial: 35863669
Drug: Prednisolone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (0.5 mg/kg/d, maximum 40 mg/d, for 14 ± 2 days)
Trial: 34294595
Drug: Durvalumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab (10 mg/kg intravenously every 2 weeks for 12 months)
Trial: 32967873
Drug: Intravenous haloperidol
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous haloperidol 2.5 mg every 8 hours, titrated to a maximum of 5 mg every 8 hours until delirium resolution or ICU discharge.
Trial: 34181750
Drug: Budesonide (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (9 mg/day for 10 weeks)
Trial: 34723163
Drug: C21 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C21 (100 mg bid for 7 days)
Trial: 33040002
Drug: Febuxostat (hyperuricaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Febuxostat (hyperuricaemia treatment)
Trial: 32598683
Drug: NSAIDs +
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs + Injectran (Chondroitin sulfate) 200 mg I.M. every other day No. 25
Trial: 32598683
Drug: NSAIDs +
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs + Fermatron 1% 2 ml I.A. with an interval of 7 days No. 3
Trial: 32598683
Drug: NSAIDs +
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NSAIDs + Injectran 200 mg I.M. every other day No. 25 + Fermatron 1% 2 ml I.A. with an interval of 7 days No. 3
Trial: 35157497
Drug: Activity monitoring
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activity monitoring with triage visits triggered by a 20% decrease in daily steps or 20% increase in heart rate.
Trial: 33582664
Drug: Colchicine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine (2 mg oral bolus followed by 0.5 mg b.i.d. for 5 days)
Trial: 36163722
Drug: Curcumin 500
RxNorm normalized name: curcumin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 500 mg per oral capsule twice daily for 1 month plus nutritional standard of care (SOC)
Trial: 36338456
Drug: Systemic decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic decolonization (topical chlorhexidine gluconate, intranasal mupirocin, oral rifampin, and oral doxycycline)
Trial: 36338456
Drug: Standard decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard decolonization (topical chlorhexidine gluconate and intranasal mupirocin)
Trial: 34371442
Drug: Maintenance of
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance of androgen deprivation therapy (ADT)
Trial: 34371442
Drug: Intermittent docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent docetaxel administration
Trial: 34371442
Drug: Suspension of
RxNorm normalized name: Suspension of heat killed (autoclaved) Mycobacterium w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension of androgen deprivation therapy (ADT)
Trial: 32438639
Drug: Concord grape
RxNorm normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concord grape juice (CGJ), 16 ounces daily for 24 weeks
Trial: 36404282
Drug: Adapted group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted group cognitive-behavioral therapy (CBT) program
Trial: 32075665
Drug: Twice-weekly haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly haemodialysis sessions
Trial: 32075665
Drug: Thrice-weekly haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-weekly haemodialysis regimen
Trial: 35771894
Drug: Ever using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ever using drugs of addiction
Trial: 34931773
Drug: 3D-printed implant
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D-printed implant overdentures
Trial: 34931773
Drug: Conventional implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional implant overdentures
Trial: 35486418
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive behavioral therapy for insomnia (ICBT‐i)
Trial: 33826992
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (writing about daily activities)
Trial: 35842062
Drug: Blood Flow
RxNorm normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood Flow Restriction (BFR) therapy with pneumatic cuff set to 80% limb occlusion pressure, performed 5 days per week for two weeks
Trial: 34834540
Drug: Standard escitalopram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard escitalopram dosing
Trial: 34834540
Drug: Dosing based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing based on validated CYP2C19 phenotypes for escitalopram metabolism
Trial: 36011930
Drug: HEUR-L (heuristic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEUR-L (heuristic learning)
Trial: 36011930
Drug: HEUR-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEUR-L
Trial: 36011930
Drug: HEUR-L and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEUR-L and PRES-T
Trial: 32533264
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of strategic mini-implants
Trial: 32533264
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of strategic mini-implants
Trial: 36092959
Drug: Antimicrobial step‐down
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial step‐down therapy (imipenem/cilastatin)
Trial: 36092959
Drug: Conventional antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional antimicrobial therapy (sulbactam plus cefoperazone)
Trial: 35251715
Drug: Maze control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maze control training in addition to selected conventional physical therapy
Trial: 36375173
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg duloxetine
Trial: 32888454
Drug: Carboplatin plus
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin plus etoposide (six cycles of intravenous carboplatin [AUC 5 mg/mL per min] on day 1 plus intravenous etoposide [100 mg/m2 from day 1 to day 3])
Trial: 32888454
Drug: Topotecan (2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (2.3 mg/m2 from day 1 to day 5, for six cycles)
Trial: 32986176
Drug: Apixaban 5
RxNorm normalized name: apixaban 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban 5 mg/12 h or 2.5 mg/12 h (after dose adjustment or in high-risk patients)
Trial: 32986176
Drug: DAPT with
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT with aspirin and clopidogrel
Trial: 33228726
Drug: losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: losartan potassium plus Keluoxin capsule (KLX)
Trial: 32925743
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) 1000 mg in 100 mL normal saline, administered intravenously over 20 minutes before skin incision
Trial: 39222701
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) - aspirin plus clopidogrel
Trial: 33678522
Drug: Atezolizumab 1200
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab 1200 mg IV plus Bevacizumab 15 mg/kg IV every 3 weeks
Trial: 39532375
Drug: Atezolizumab monotherapy
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab monotherapy
Trial: 34251103
Drug: Longidaza (rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longidaza (rectal suppositories of 3000 IU)
Trial: 34251103
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard postoperative therapy with tamsulosin and fluoroquinolone)
Trial: 616886749
Drug: Compound azintamide
RxNorm normalized name: Azintamide
DrugBank: Azintamide (DB13992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound azintamide enteric‐coated tablets
Trial: 616886749
Drug: Compound digestive
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound digestive enzyme capsules
Trial: 33369909
Drug: Leu/Met/Sil 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leu/Met/Sil 1.0 in participants with baseline insulin ≥12mU/L
Trial: 34789403
Drug: ap1gen (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ap1gen (low-dose recombinant pertussis-only vaccine containing 1 μg PTgen and 1 μg FHA)
Trial: 34789403
Drug: Tdap1gen (tetanus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap1gen (tetanus, reduced-dose diphtheria combined to ap1gen)
Trial: 34789403
Drug: Tdap2gen (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap2gen (combined to recombinant pertussis containing 2 μg PTgen and 5 μg FHA)
Trial: 34789403
Drug: TdaP5gen (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TdaP5gen (licensed recombinant TdaP vaccine containing 5 μg PTgen and 5 μg FHA)
Trial: 34789403
Drug: Tdap8chem (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap8chem (licensed Tdap vaccine containing 8 μg of chemically inactivated pertussis toxoid, 8 μg FHA, and 2.5 μg pertactin)
Trial: 35343648
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m2 once-a-week with radiotherapy
Trial: 35343648
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 once every-3-weeks with radiotherapy
Trial: 34059488
Drug: lenalidomide treatment
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: lenalidomide treatment
Trial: 32532291
Drug: Enadenotucirev (EnAd)
RxNorm normalized name: Enadenotucirev
DrugBank: Enadenotucirev (DB14873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enadenotucirev (EnAd) in combination with chemoradiotherapy
Trial: 34453840
Drug: Drug (pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug (pharmacological rate control)
Trial: 35119113
Drug: Solution-focused psychoeducation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-focused psychoeducation (SFP)
Trial: 35119113
Drug: Childbirth preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Childbirth preparation training (CPT)
Trial: 32491964
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) (G2)
Trial: 34184823
Drug: Sodium-glucose co-transporter
RxNorm normalized name: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Trial: 34535959
Drug: Glycine supplementation
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glycine supplementation (7 g twice daily for 4 months)
Trial: 34535959
Drug: BCAA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BCAA supplementation (7 g twice daily for 4 months)
Trial: 33723086
Drug: Axxess bifurcation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axxess bifurcation device (Biosensors) in combination with Absorb BVS (Abbott Vascular)
Trial: 35704479
Drug: HSIL treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HSIL treatment (including office-based ablative procedures, ablation or excision under anesthesia, or topical fluorouracil or imiquimod)
Trial: 35704479
Drug: Active monitoring
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active monitoring without treatment
Trial: 36031439
Drug: TXA (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TXA (10 mg/kg bolus dose 15 min prior to incision and another similar dose after 3 h)
Trial: 35909585
Drug: Traditional breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional breathing therapy (TG)
Trial: 32720582
Drug: High-intensity statin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity statin, ezetimibe, and high-dose proprotein convertase subtilisin/kexin type 9 inhibitor
Trial: 35082351
Drug: Physical-possession condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical-possession condition (participants possessed a tangible placebo analgesic oil)
Trial: 35082351
Drug: Psychological-possession condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychological-possession condition (participants possessed a coupon for a placebo analgesic oil)
Trial: 33548329
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 0.5 mg dexamethasone and 800 mg ibuprofen
Trial: 33164611
Drug: Upadacitinib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib 7.5 mg daily
Trial: 33164611
Drug: Methotrexate 7.5
RxNorm normalized name: methotrexate 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate 7.5 mg/week (titrated to ≤15 mg/week)
Trial: 36148320
Drug: 3 μg/(kg·min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 μg/(kg·min) mivacurium (group M1)
Trial: 36148320
Drug: 6 μg/(kg·min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 μg/(kg·min) mivacurium (group M2)
Trial: 36148320
Drug: 9 μg/(kg·min)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 μg/(kg·min) mivacurium (group M3)
Trial: 35904950
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy followed by laser therapy (980 nm DL, 1 W, continuous wave mode, 20 sec per tooth side, repeated twice at 5‐7 day intervals)
Trial: 35904950
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy followed by laser therapy
Trial: 32412917
Drug: Prescription Tongxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Tongxin
Trial: 32412917
Drug: Shexiang Baoxin
RxNorm normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shexiang Baoxin Pill
Trial: 32484850
Drug: SENATOR software-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SENATOR software-guided medication optimization plus standard care
Trial: 33542551
Drug: Partial cystectomy
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial cystectomy and adjunctive medical therapy (Group A)
Trial: 33542551
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy alone (Group B)
Trial: 32074624
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) + Treatment as Usual (TAU)
Trial: 32074624
Drug: Specialized Attention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specialized Attention Therapy (SAT) + Treatment as Usual (TAU)
Trial: 35651925
Drug: Traditional drug
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional drug therapy
Trial: 36082508
Drug: NRPT 1X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRPT 1X (recommended daily dose)
Trial: 36082508
Drug: NRPT 2X
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRPT 2X (double dose)
Trial: 35410939
Drug: internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: internet-delivered cognitive behavioural therapy (iCBT)
Trial: 34111898
Drug: Tablet Computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet Computer